Results 171 to 180 of about 17,658 (223)

Survival after resection of pancreatic cancer is similar with neoadjuvant gemcitabine-nab-paclitaxel or mFOLFIRINOX but one size will not fit all in the future. [PDF]

Hepatobiliary Surg Nutr
Hernandez S, Maker AV.
europepmc   +1 more source

Efficacy and safety of nab-paclitaxel plus PD-1 inhibitor in elderly patients with advanced squamous lung cancer. [PDF]

BMC Cancer
Qian H, Jiang J, Li S, Ni C, Chen Y, Song Y, Zhu T, Yan Y.   +7 more
europepmc   +1 more source

Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial'. [PDF]

ESMO Open
Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van Cutsem E, Bekaii-Saab T, Zhang L, Li J, Chen H, Maxwell F, Wainberg ZA, Melisi D.   +19 more
europepmc   +1 more source

Second-line nab-paclitaxel and gemcitabine for advanced pancreatic cancer following FOLFIRINOX: outcomes and insights. [PDF]

Am J Cancer Res
Merc Cetınkaya A, Tatlı AM, Goktas Aydın S, Kılıckap S, Bılıcı A, Bırıcık FS, Kostek O, Kayıkcıoglu E, Paydas S, Artac M, Teker F, Cıl T, Kaplan MA, Hacıbekıroglu İ, Geredelı C, Bayram E, Altıntas YE, Celebı AS, Kocak MZ, Arak H, Arslan Benlı B, Arvas H, Dınc Sonusen S, Sezgın Goksu S.   +23 more
europepmc   +1 more source

Efficacy and Safety of Combination Therapy With Immune Checkpoint Inhibitors and Chemotherapy With Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer: A Systematic Review. [PDF]

Cancer Med
Sohrabi H, Ghavam SM, Azadnajafabad S, Rezaei N.   +3 more
europepmc   +1 more source

Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study. [PDF]

BMJ Oncol
Thambamroong T, Meesart R, Prasongsook N, Ngamphaiboon N, Akewanlop C, Tanasanvimon S, Phavirunsiri J, Pakvisal N, Korphaisarn K, Sathitruangsak C, Siripoon T, Simseekeaw P, Charonpongsuntorn C, Wirasorn K, Kerkarchachai G, Eiamprapaporn P, Suksombooncharoen T, Sa-Nguansai S, Patiluntakankul A, Sirachainan E.   +19 more
europepmc   +1 more source

Bevacizumab plus nab-paclitaxel and platinum as second-line therapy for driver-gene-negative non-squamous non-small cell lung cancer after immunochemotherapy: A prospective single-arm single-centre study. [PDF]

Clin Transl Med
Lin Y, Yu Y, Hu Z, Wei C, Wang Z, Zhang Y, Wu Z, Yu B, Zhao X, Yu H, Wu X, Wang H, Wang J.   +12 more
europepmc   +1 more source

Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer. [PDF]

Clin Mol Hepatol
Kim D, Sim NS, Woo S, Kim MH, Lee CK, Hong SS, Kim SH, Hwang HK, Kang CM, Lee WJ, Jo JH, Chung T, Hwang S, Kang B, Kim JS, Kwon CI, Kim S, Chon HJ, Kim CG, Park YN, Choi HJ.   +20 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nab-Paclitaxel: A Flattering Facelift

Critical Reviews in Oncology/Hematology, 2014
The application of nanotechnology in oncology has increased the efficacy and efficiency of some cytotoxic agents. The paradigm in this field is nab-paclitaxel, a soluble form of paclitaxel that is linked to albumin nanoparticles. The development of nanotechnology as a delivery system for paclitaxel has provided better pharmacokinetic and ...
Antonio Viúdez, Natalia Ramírez
exaly   +3 more sources

Nab-Paclitaxel related cystoid macular edema.

La Clinica terapeutica, 2022
Nab-paclitaxel is a chemotherapeutic drug used to treat various solid malignant tumors. It was conceived with a solvent free formulation to overcome toxicity events and hypersensitivity reactions associated with paclitaxel. However, it still carries ocular adverse effects.
Di Pippo, M, Di Staso, F, De Ponte, C, Fragiotta, S, Abdolrahimzadeh, S   +4 more
openaire   +2 more sources